The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Open accessAbstract
Rituximab is an anti-CD20 chimeric mAb effective for the treatment of B-NHL. It can lyse lymphoma cells in vitro through both C- and Ab-dependent cellular cytotoxicity. The mechanism of action of rituximab in vivo is however still unclear. We have set up a new in vivo model in nonimmunodeficient mice by stable transduction of the human CD20 cDNA in the murine lymphoma line EL4. Animals injected i.v. with the EL4-CD20+ lymphoma cells died within 30 days with evident liver, spleen, and bone marrow involvement, confirmed by immunohistochemistry and PCR analysis. A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cured 100% of the animals. Indeed, at week 4 after tumor cell inoculation, CD20+ cells were undetectable in all organs analyzed in rituximab-treated animals, as determined by immunohistochemistry and PCR. Rituximab had no direct effect on tumor growth in vitro. Depletion of either NK cells or neutrophils or both in tumor-injected animals did not affect the therapeutic activity of the drug. Similarly, rituximab was able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent. In contrast, the protective activity of rituximab or the 1F5 Ab was completely abolished in syngeneic knockout animals lacking C1q, the first component of the classical pathway of C (C1qa−/−). These data demonstrate that C activation is fundamental for rituximab therapeutic activity in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 2×
“In addition, a recent model of human lymphoma in nude mice has suggested that the Fc R -chain, common to both Fc RI and Fc RIII, is required for the full therapeutic activity of the Ab (13).”
BackgroundDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
Botto, M., Dell' Agnola, C., Bygrave, A. E., Thompson, E. M., Cook, H. T., Petry, F., Loos, M., Pandolfi, P. P., & Walport, M. J. (1998) · Nature Genetics · doi:10.1038/ng0598-56 · Cited by 1,434
Self-citationRepeat-induced gene silencing in mammals
Garrick, D., Fiering, S., Martin, D. I. K., & Whitelaw, E. (1998) · Nature Genetics · doi:10.1038/ng0198-56 · Cited by 887
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response
Garlanda, C., Hirsch, E., Bozza, S., Salustri, A., De Acetis, M., Nota, R., Maccagno, A., Riva, F., Bottazzi, B., Peri, G., et al. (2002) · Nature · doi:10.1038/nature01195 · Cited by 669
Self-citationGolay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.-M., Bernasconi, S., Tedesco, F., Rambaldi, A., & Introna, M. (2000) · Blood · doi:10.1182/blood.v95.12.3900 · Cited by 604
Self-citationApoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 576
Foran, J. M., Rohatiner, A. Z. S., Cunningham, D., Popescu, R. A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P. W. M., Gisselbrecht, C., Reyes, F., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.317 · Cited by 472
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428
Self-citationComplement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P. W. M., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.-P., Jacob, M.-C., Sotto, J.-J., Leroux, D., Bensa, J.-C., & Plumas, J. (2003) · Blood · doi:10.1182/blood-2002-02-0469 · Cited by 372
Byrd, J. C., Kitada, S., Flinn, I. W., Aron, J. L., Pearson, M., Lucas, D., & Reed, J. C. (2002) · Blood · doi:10.1182/blood.v99.3.1038 · Cited by 367
Complement activation plays a key role in the side‐effects of rituximab treatment
Van Der Kolk, L. E., Grillo‐López, A. J., Baars, J. W., Hack, C. E., & Van Oers, M. H. J. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03166.x · Cited by 327
Ioan-Facsinay, A., de Kimpe, S. J., Hellwig, S. M. M., van Lent, P. L., Hofhuis, F. M. A., van Ojik, H. H., Sedlik, C., da Silveira, S. A., Gerber, J., de Jong, Y. F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00294-7 · Cited by 304
Engineered Antibodies with Increased Activity to Recruit Complement
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291
Shushakova, N., Skokowa, J., Schulman, J., Baumann, U., Zwirner, J., Schmidt, R. E., & Gessner, J. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16577 · Cited by 284
Anderson, D. R., Grillo-López, A., Varns, C., Chambers, K. S., & Hanna, N. (1997) · Biochemical Society Transactions · doi:10.1042/bst0250705 · Cited by 248
The role of complement in inflammation and adaptive immunity
Barrington, R., Zhang, M., Fischer, M., & Carroll, M. C. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1800101.x · Cited by 232
Pedersen, I. M., Buhl, A. M., Klausen, P., Geisler, C. H., & Jurlander, J. (2002) · Blood · doi:10.1182/blood.v99.4.1314 · Cited by 219
Immune evasion of tumor cells using membrane-bound complement regulatory proteins
Gorter, A., & Meri, S. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01537-6 · Cited by 206
Bellosillo, B., Villamor, N., López-Guillermo, A., Marcé, S., Esteve, J., Campo, E., Colomer, D., & Montserrat, E. (2001) · Blood · doi:10.1182/blood.v98.9.2771 · Cited by 205
Di Gaetano, N., Xiao, Y., Erba, E., Bassan, R., Rambaldi, A., Golay, J., & Introna, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03014.x · Cited by 198
Self-citationGolay, J. T., Clark, E. A., & Beverley, P. C. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.6.3795 · Cited by 175
Self-citationTanaka, T., Kitamura, F., Nagasaka, Y., Kuida, K., Suwa, H., & Miyasaka, M. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.1103 · Cited by 174
Pruijt, J. F. M., Verzaal, P., van Os, R., de Kruijf, E.-J. F. M., van Schie, M. L. J., Mantovani, A., Vecchi, A., Lindley, I. J. D., Willemze, R., Starckx, S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092112999 · Cited by 169
Self-citationValerius, T., Repp, R., de Wit, T., Berthold, S., Platzer, E., Kalden, Jr., Gramatzki, M., & van de Winkel, J. (1993) · Blood · doi:10.1182/blood.v82.3.931.931 · Cited by 165
Introna, M., Barbui, A. M., Bambacioni, F., Casati, C., Gaipa, G., Borleri, G., Bernasconi, S., Barbui, T., Golay, J., Biondi, A., et al. (2000) · Human Gene Therapy · doi:10.1089/10430340050015798 · Cited by 142
Self-citationKennedy, A. D., Solga, M. D., Schuman, T. A., Chi, A. W., Lindorfer, M. A., Sutherland, W. M., Foley, P. L., & Taylor, R. P. (2003) · Blood · doi:10.1182/blood-2002-03-0876 · Cited by 141
Antibody-Targeted Immunotherapy for Treatment of Malignancy
White, C. A., Weaver, R. L., & Grillo-López, A. J. (2001) · Annual Review of Medicine · doi:10.1146/annurev.med.52.1.125 · Cited by 130
Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects
Rose, A. L., Smith, B. E., & Maloney, D. G. (2002) · Blood · doi:10.1182/blood.v100.5.1765.h81702001765_1765_1773 · Cited by 129
Miwa, T., Zhou, L., Hilliard, B. A., Molina, H. D., & Song, W. (2002) · Blood · doi:10.1182/blood.v99.10.3707 · Cited by 87
Clinical status and optimal use of rituximab for B-cell lymphomas.
McLaughlin, P. J., White, C. A., Grillo-López, A. J., & Maloney, D. G. (1998) · PubMed · Cited by 84
Mac-1 (CD11b/CD18) is crucial for effective Fc receptor–mediated immunity to melanoma
van Spriel, A. B., van Ojik, H. H., Bakker, A., Jansen, M., & van de Winkel, J. G. J. (2002) · Blood · doi:10.1182/blood.v101.1.253 · Cited by 79
Trcka, J., Moroi, Y., Clynes, R., Goldberg, S. M., Bergtold, A., Perales, M., Ma, M., Ferrone, C. R., Carroll, M. C., Ravetch, J. V., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00327-8 · Cited by 69
Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils
van der Kolk, L., de Haas, M., Grillo-López, A. J., Baars, J. W., & van Oers, M. (2002) · Leukemia · doi:10.1038/sj.leu.2402424 · Cited by 68
Emerging information on the use of rituximab in chronic lymphocytic leukemia
Keating, M. J., O'Brien, S. M., & Albitar, M. X. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30142 · Cited by 62
A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody
Gazzano, H., Ralph, P., Ryskamp, T., Chen, A. B., & Mukku, V. R. (1997) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00002-1 · Cited by 55
Runyon, K., Lee, K., Zuberek, K., Collins, M. A., Leonard, J. P., & Dunussi‐Joannopoulos, K. (2001) · Blood · doi:10.1182/blood.v97.8.2420 · Cited by 33
Negative Regulation of Expression and Function of FcγRIII by CD3ζ in Murine NK Cells
Arase, H., Suenaga, T., Arase, N., Kimura, Y., Ito, K., Shiina, R., Ohno, H., & Saito, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.21 · Cited by 32
Cited by
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Metadata
- Authors
- Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-08-01
- Volume
- 171
- Issue
- 3
- Pages
- 1581-1587
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2168648203
- Cited by
- 576
- References
- 42
- FWCI
- 22.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.